EMEA gives details of Lunivia withdrawal
This article was originally published in Scrip
Executive Summary
Sepracor withdrew its EU marketing authorisation application for Lunivia (eszopiclone) 2mg and 3mg tablets in May because the CHMP advised that the product could not be treated as a new active substance (scripnews.com, May 19th, 2009).